Yuval Cohen Sells 17,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) CEO Yuval Cohen sold 17,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $171,360.00. Following the sale, the chief executive officer owned 157,316 shares of the company’s stock, valued at approximately $1,585,745.28. The trade was a 9.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Corbus Pharmaceuticals Stock Up 0.5%

Corbus Pharmaceuticals stock opened at $9.51 on Wednesday. The business’s 50-day simple moving average is $8.79 and its 200 day simple moving average is $9.06. The stock has a market cap of $177.55 million, a price-to-earnings ratio of -1.54 and a beta of 2.59. Corbus Pharmaceuticals Holdings, Inc. has a 12-month low of $7.12 and a 12-month high of $20.56.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.55). As a group, sell-side analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -5.22 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Orbimed Advisors LLC grew its stake in Corbus Pharmaceuticals by 8.8% in the first quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock valued at $16,313,000 after acquiring an additional 140,000 shares during the period. Prosight Management LP raised its position in shares of Corbus Pharmaceuticals by 99.1% during the fourth quarter. Prosight Management LP now owns 683,872 shares of the biopharmaceutical company’s stock worth $5,567,000 after purchasing an additional 340,472 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Corbus Pharmaceuticals by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock valued at $7,742,000 after purchasing an additional 12,535 shares in the last quarter. Armistice Capital LLC lifted its holdings in shares of Corbus Pharmaceuticals by 179.2% during the 4th quarter. Armistice Capital LLC now owns 536,000 shares of the biopharmaceutical company’s stock valued at $4,363,000 after purchasing an additional 344,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Corbus Pharmaceuticals by 230.5% in the 4th quarter. Renaissance Technologies LLC now owns 354,300 shares of the biopharmaceutical company’s stock valued at $2,884,000 after purchasing an additional 247,100 shares during the period. 64.64% of the stock is currently owned by institutional investors.

More Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target, while the broader analyst consensus remains “Moderate Buy” with an average target of $41.12. The firm also projects a return to profitability by 2030, despite near-term losses. HC Wainwright Cuts Corbus Pharmaceuticals Price Target
• Positive Sentiment: Several institutional investors increased their positions, including OrbiMed Advisors, Armistice Capital, Prosight Management, ADAR1 Capital Management, and Renaissance Technologies. Institutional ownership stands at approximately 64.6%, which may offer some support for the shares.
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio. Because both the current and prior short-interest figures are listed as zero, the reported percentage increase is not meaningful and does not indicate notable short-covering or bearish positioning.
• Negative Sentiment: HC Wainwright reduced EPS forecasts across 2026–2030: 2026 is now expected at a $6.11 loss per share versus a prior $4.99 loss, while 2027–2029 loss estimates also widened materially. Its 2030 forecast fell to $0.15 from $1.29, signaling a slower path to profitability. Analysts Offer Insights on Corbus Pharmaceuticals
• Negative Sentiment: Oppenheimer lowered its price target to $48 from $52, and HC Wainwright cut its target to $35 from $40, although both firms remain positive on CRBP. Oppenheimer Cuts Corbus Pharmaceuticals Price Target
• Negative Sentiment: CEO Yuval Cohen sold 17,000 shares and CFO Sean Moran sold 12,000 shares at $10.08 per share, reducing their direct holdings by roughly 9.8% and 12.4%, respectively. The company also recently reported a quarterly loss of $1.81 per share, worse than the $1.26 analyst consensus.

Analyst Ratings Changes

A number of brokerages have issued reports on CRBP. Wedbush reduced their price objective on shares of Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 27th. Mizuho dropped their target price on shares of Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating for the company in a research report on Tuesday, June 23rd. Oppenheimer reduced their price target on Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Wall Street Zen cut Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, HC Wainwright dropped their price objective on Corbus Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating for the company in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Corbus Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $41.12.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.